Secondary loss of effectiveness among rheumatoid arthritis patients treated with tumour necrosis factor inhibitors

被引：0

作者：

Aaltonen, K. ^{[1
]}

Isomaki, P. ^{[2
,3
]}

Joensuu, J. ^{[1
]}

Sokka, T. ^{[4
,5
]}

Peltomaa, R. ^{[6
]}

Piril, L. ^{[7
]}

Varjolahti-Lehtinen, T. ^{[8
]}

Uutela, T. ^{[9
]}

Malmi, T. ^{[10
]}

Ekman, P. ^{[11
]}

Kononoff, A. ^{[12
]}

Eklund, K. ^{[6
,13
]}

机构：

[1] Univ Helsinki, Fac Pharm, Helsinki, Finland

[2] Tampere Univ Hosp, Dept Med, Tampere, Finland

[3] Univ Tampere, Fac Med, Tampere, Finland

[4] Jyvaskyla Cent Hosp, Dept Med, Jyvaskyla, Finland

[5] Univ Eastern Finland, Fac Hlth Sci, Kuopio, Finland

[6] Univ Helsinki, Dept Med, Cent Hosp, Helsinki, Finland

[7] Turku Univ Hosp, Dept Med, Turku, Finland

[8] Tampere City Hosp, Dept Med, Tampere, Finland

[9] Lapland Cent Hosp, Dept Med, Rovaniemi, Finland

[10] Seinajoki Cent Hosp, Dept Med, Seinajoki, Finland

[11] Rauma Cent Hosp, Dept Med, Rauma, Finland

[12] Kuopio Univ Hosp, Dept Med, Kuopio, Finland

[13] Univ Helsinki, Fac Med, Helsinki, Finland

来源：

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2017年 / 46卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：419 / 420

页数：2

共 50 条

[21] Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis
James R. Spalding
Joel Hay
[J]. PharmacoEconomics, 2006, 24 : 1221 - 1232
[22] Cost effectiveness of tumour necrosis factor-α inhibitors as first-line agents in rheumatoid arthritis
Spalding, James R.
Hay, Joel
[J]. PHARMACOECONOMICS, 2006, 24 (12) : 1221 - 1232
[23] Medication Effectiveness with the Use of Tumor Necrosis Factor Inhibitors Among Texas Medicaid Patients Diagnosed with Rheumatoid Arthritis
Oladapo, Abiola
Barner, Jamie C.
Lawson, Kenneth A.
Novak, Suzanne
Rascati, Karen L.
Richards, Kristin M.
Harrison, David J.
[J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2014, 20 (07): : 657 - 667
[24] Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe
Holden, S. E.
Currie, C. J.
Lennon, M.
Reynolds, A. V.
Moots, R. J.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 679 - 684
[25] MiRNAs CORRELATE WITH IMPROVEMENT IN DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS ON TUMOUR NECROSIS FACTOR INHIBITORS
David, T.
Nair, N.
Oliver, J.
Schordan, E.
Firat, H.
Hyrich, K.
Morgan, A.
Wilson, A. G.
Isaacs, J. D.
Plant, D.
Barton, A.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 409 - 409
[26] Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis
Barrera, P
Oyen, WJG
Boerman, OC
van Riel, PLCM
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) : 825 - 828
[27] When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?
Smolen, Josef S.
Weinblatt, Michael E.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) : 1497 - 1498
[28] TUMOUR NECROSIS FACTOR INHIBITORS AND THEIR IMPACT ON DIABETES MELLITUS AMONG PATIENTS WITH PSORIATIC ARTHRITIS
Mantravadi, S.
George, M.
Ogdie, A.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1599 - 1599
[29] Gene expression profiling of rheumatoid arthritis patients treated with anti-tumour necrosis factor
Coenen, Marieke J. H.
Toonen, Erik J. M.
Batliwalla, Franak
van Riel, Piet L. C. M.
Kievit, Wietske
Veltman, Joris A.
Eijsbouts, Agnes M. M.
Gilissen, Christian F. H. A.
Damle, Aarti
Scheffer, Hans
Radstake, Timoth R. D. J.
Gregersen, Peter K.
Barrera, Pilar
Franke, Barbara
[J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S615 - S616
[30] The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients
Berkhout, Lea C.
l'Ami, Merel J.
Krieckaert, Charlotte L. M.
Vogelzang, Erik H.
Kos, Dorien
Nurmohamed, Michael T.
Wolbink, Gerrit J.
Rispens, Theo
[J]. RHEUMATOLOGY, 2020, 59 (07) : 1703 - 1708

← 1 2 3 4 5 →